TapewireFind a company

person · Reporting owner

Mathers James

Disclosed activity across 1 company

Tapewire entity
148884
SEC CIK
0001676166

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BIOLIFE SOLUTIONS INCBLFS · Entity 4614Chief Revenue OfficerMay 28, 2020June 02, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIOLIFE SOLUTIONS INC

Report date May 28, 2020 · Filed June 02, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect19,856 Reported balance After 2020-05-28 transaction · row 1
1 source row

Row 1 · 2020-05-28 · Sale · Disposed 121 · Balance 19,856

F1: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Filing footnotes · ownership attribution and instrument terms

F1: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 04, 2019 Filed Sep 6, 2019 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,500 $20.03 $50,075.00
Disclosure

SEC source: 0001437749-19-017956 · rdgdoc.xml · nonDerivative · entry 4

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.51 to $20.42, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range

Read SEC document
September 04, 2019 Filed Sep 6, 2019 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionCommon Stock 2,500 $1.64 $4,100.00
Disclosure

SEC source: 0001437749-19-017956 · rdgdoc.xml · nonDerivative · entry 3

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 03, 2019 Filed Sep 6, 2019 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionEmployee Stock Option · Derivative 2,500 $0.00 Strike: $1.64 $0.00
Disclosure

SEC source: 0001437749-19-017956 · rdgdoc.xml · derivative · entry 7

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,113

Underlying: Common Stock · 2,500 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 03, 2019 Filed Sep 6, 2019 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,500 $20.07 $50,175.00
Disclosure

SEC source: 0001437749-19-017956 · rdgdoc.xml · nonDerivative · entry 2

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.14, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
September 03, 2019 Filed Sep 6, 2019 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionCommon Stock 2,500 $1.64 $4,100.00
Disclosure

SEC source: 0001437749-19-017956 · rdgdoc.xml · nonDerivative · entry 1

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 22, 2019 Filed Aug 23, 2019 00:11 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionEmployee Stock Option · Derivative 2,500 $0.00 Strike: $1.64 $0.00
Disclosure

SEC source: 0001437749-19-017313 · rdgdoc.xml · derivative · entry 9

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,613

Underlying: Common Stock · 2,500 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 22, 2019 Filed Aug 23, 2019 00:11 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,500 $20.77 $51,925.00
Disclosure

SEC source: 0001437749-19-017313 · rdgdoc.xml · nonDerivative · entry 6

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2019.

Read SEC document
August 22, 2019 Filed Aug 23, 2019 00:11 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionCommon Stock 2,500 $1.64 $4,100.00
Disclosure

SEC source: 0001437749-19-017313 · rdgdoc.xml · nonDerivative · entry 5

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 21, 2019 Filed Aug 23, 2019 00:11 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionEmployee Stock Option · Derivative 2,500 $0.00 Strike: $1.64 $0.00
Disclosure

SEC source: 0001437749-19-017313 · rdgdoc.xml · derivative · entry 8

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,113

Underlying: Common Stock · 2,500 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 21, 2019 Filed Aug 23, 2019 00:11 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,500 $20.52 $51,300.00
Disclosure

SEC source: 0001437749-19-017313 · rdgdoc.xml · nonDerivative · entry 4

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2019.

Read SEC document
August 21, 2019 Filed Aug 23, 2019 00:11 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionCommon Stock 2,500 $1.64 $4,100.00
Disclosure

SEC source: 0001437749-19-017313 · rdgdoc.xml · nonDerivative · entry 3

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 20, 2019 Filed Aug 23, 2019 00:11 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionEmployee Stock Option · Derivative 2,500 $0.00 Strike: $1.64 $0.00
Disclosure

SEC source: 0001437749-19-017313 · rdgdoc.xml · derivative · entry 7

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,613

Underlying: Common Stock · 2,500 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 20, 2019 Filed Aug 23, 2019 00:11 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,500 $20.06 $50,150.00
Disclosure

SEC source: 0001437749-19-017313 · rdgdoc.xml · nonDerivative · entry 2

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2019.

Read SEC document
August 20, 2019 Filed Aug 23, 2019 00:11 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionCommon Stock 2,500 $1.64 $4,100.00
Disclosure

SEC source: 0001437749-19-017313 · rdgdoc.xml · nonDerivative · entry 1

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 08, 2019 Filed Aug 9, 2019 00:04 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionEmployee Stock Option · Derivative 2,500 $0.00 Strike: $1.64 $0.00
Disclosure

SEC source: 0001437749-19-016096 · rdgdoc.xml · derivative · entry 9

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,113

Underlying: Common Stock · 2,500 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 08, 2019 Filed Aug 9, 2019 00:04 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,500 $18.21 $45,525.00
Disclosure

SEC source: 0001437749-19-016096 · rdgdoc.xml · nonDerivative · entry 6

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2019.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.1705 to $18.30, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
August 08, 2019 Filed Aug 9, 2019 00:04 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionCommon Stock 2,500 $1.64 $4,100.00
Disclosure

SEC source: 0001437749-19-016096 · rdgdoc.xml · nonDerivative · entry 5

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 07, 2019 Filed Aug 9, 2019 00:04 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionEmployee Stock Option · Derivative 2,500 $0.00 Strike: $1.64 $0.00
Disclosure

SEC source: 0001437749-19-016096 · rdgdoc.xml · derivative · entry 8

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,613

Underlying: Common Stock · 2,500 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 07, 2019 Filed Aug 9, 2019 00:04 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,500 $18.00 $45,000.00
Disclosure

SEC source: 0001437749-19-016096 · rdgdoc.xml · nonDerivative · entry 4

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.93 to $18.09, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
August 07, 2019 Filed Aug 9, 2019 00:04 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionCommon Stock 2,500 $1.64 $4,100.00
Disclosure

SEC source: 0001437749-19-016096 · rdgdoc.xml · nonDerivative · entry 3

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 06, 2019 Filed Aug 9, 2019 00:04 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionEmployee Stock Option · Derivative 2,500 $0.00 Strike: $1.64 $0.00
Disclosure

SEC source: 0001437749-19-016096 · rdgdoc.xml · derivative · entry 7

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,113

Underlying: Common Stock · 2,500 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 06, 2019 Filed Aug 9, 2019 00:04 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,500 $17.87 $44,675.00
Disclosure

SEC source: 0001437749-19-016096 · rdgdoc.xml · nonDerivative · entry 2

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.84 to $17.98, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
August 06, 2019 Filed Aug 9, 2019 00:04 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionCommon Stock 2,500 $1.64 $4,100.00
Disclosure

SEC source: 0001437749-19-016096 · rdgdoc.xml · nonDerivative · entry 1

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 25, 2019 Filed Jul 26, 2019 00:14 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionEmployee Stock Option · Derivative 2,500 $0.00 Strike: $1.64 $0.00
Disclosure

SEC source: 0001437749-19-014689 · rdgdoc.xml · derivative · entry 9

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,613

Underlying: Common Stock · 2,500 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 25, 2019 Filed Jul 26, 2019 00:14 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,500 $19.71 $49,275.00
Disclosure

SEC source: 0001437749-19-014689 · rdgdoc.xml · nonDerivative · entry 6

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2019.

Read SEC document
July 25, 2019 Filed Jul 26, 2019 00:14 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionCommon Stock 2,500 $1.64 $4,100.00
Disclosure

SEC source: 0001437749-19-014689 · rdgdoc.xml · nonDerivative · entry 5

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 24, 2019 Filed Jul 26, 2019 00:14 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionEmployee Stock Option · Derivative 2,500 $0.00 Strike: $1.64 $0.00
Disclosure

SEC source: 0001437749-19-014689 · rdgdoc.xml · derivative · entry 8

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,113

Underlying: Common Stock · 2,500 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 24, 2019 Filed Jul 26, 2019 00:14 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,500 $18.98 $47,450.00
Disclosure

SEC source: 0001437749-19-014689 · rdgdoc.xml · nonDerivative · entry 4

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.93 to $19.10, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 24, 2019 Filed Jul 26, 2019 00:14 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionCommon Stock 2,500 $1.64 $4,100.00
Disclosure

SEC source: 0001437749-19-014689 · rdgdoc.xml · nonDerivative · entry 3

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 23, 2019 Filed Jul 26, 2019 00:14 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionEmployee Stock Option · Derivative 2,500 $0.00 Strike: $1.64 $0.00
Disclosure

SEC source: 0001437749-19-014689 · rdgdoc.xml · derivative · entry 7

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,613

Underlying: Common Stock · 2,500 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 23, 2019 Filed Jul 26, 2019 00:14 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,500 $18.38 $45,950.00
Disclosure

SEC source: 0001437749-19-014689 · rdgdoc.xml · nonDerivative · entry 2

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.35 to $18.575, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 23, 2019 Filed Jul 26, 2019 00:14 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionCommon Stock 2,500 $1.64 $4,100.00
Disclosure

SEC source: 0001437749-19-014689 · rdgdoc.xml · nonDerivative · entry 1

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 11, 2019 Filed Jul 12, 2019 00:06 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionEmployee Stock Option · Derivative 2,500 $0.00 Strike: $1.64 $0.00
Disclosure

SEC source: 0001437749-19-013873 · rdgdoc.xml · derivative · entry 9

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,113

Underlying: Common Stock · 2,500 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 11, 2019 Filed Jul 12, 2019 00:06 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,500 $17.15 $42,875.00
Disclosure

SEC source: 0001437749-19-013873 · rdgdoc.xml · nonDerivative · entry 6

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2019.

Read SEC document
July 11, 2019 Filed Jul 12, 2019 00:06 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionCommon Stock 2,500 $1.64 $4,100.00
Disclosure

SEC source: 0001437749-19-013873 · rdgdoc.xml · nonDerivative · entry 5

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 10, 2019 Filed Jul 12, 2019 00:06 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionEmployee Stock Option · Derivative 2,500 $0.00 Strike: $1.64 $0.00
Disclosure

SEC source: 0001437749-19-013873 · rdgdoc.xml · derivative · entry 8

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,613

Underlying: Common Stock · 2,500 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 10, 2019 Filed Jul 12, 2019 00:06 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,500 $18.08 $45,200.00
Disclosure

SEC source: 0001437749-19-013873 · rdgdoc.xml · nonDerivative · entry 4

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2019.

Read SEC document
July 10, 2019 Filed Jul 12, 2019 00:06 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionCommon Stock 2,500 $1.64 $4,100.00
Disclosure

SEC source: 0001437749-19-013873 · rdgdoc.xml · nonDerivative · entry 3

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 09, 2019 Filed Jul 12, 2019 00:06 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionEmployee Stock Option · Derivative 2,500 $0.00 Strike: $1.64 $0.00
Disclosure

SEC source: 0001437749-19-013873 · rdgdoc.xml · derivative · entry 7

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,113

Underlying: Common Stock · 2,500 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 09, 2019 Filed Jul 12, 2019 00:06 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,500 $17.94 $44,850.00
Disclosure

SEC source: 0001437749-19-013873 · rdgdoc.xml · nonDerivative · entry 2

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2019.

Read SEC document
July 09, 2019 Filed Jul 12, 2019 00:06 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionCommon Stock 2,500 $1.64 $4,100.00
Disclosure

SEC source: 0001437749-19-013873 · rdgdoc.xml · nonDerivative · entry 1

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 25, 2019 Filed Feb 28, 2019 02:39 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantRestricted Stock Award · Derivative 8,217 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001437749-19-003526 · rdgdoc.xml · derivative · entry 2

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,217

Underlying: Common Stock · 8,217 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

Read SEC document
February 25, 2019 Filed Feb 28, 2019 02:39 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 8,217 Not disclosed Not disclosed
Disclosure

SEC source: 0001437749-19-003526 · rdgdoc.xml · nonDerivative · entry 1

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,384

F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

Read SEC document
March 08, 2018 Filed Mar 9, 2018 22:02 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantEmployee Stock Option · Derivative 114,613 $0.00 Strike: $1.64 $0.00
Disclosure

SEC source: 0001144204-18-013911 · tv488200_4.xml · derivative · entry 1

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,613

Underlying: Common Stock · 114,613 shares

Expires 2021-12-20

F1 · derivative.exercise_date: As disclosed in the registrants annual report on Form 10-K for the year ended December 31, 2016, on December 20, 2016, the reporting person was granted an option to purchase 114,613 shares of common stock. The option vests in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 57,307 shares vested on March 8, 2018 and 57,306 shares will vest on March 8, 2019. No Form 4 filing was required upon the initial grant of the option because the option was subject to vesting based on conditions that were not tied to the passage of time and continued employment and not tied directly to the market price of the registrant's common stock.

Read SEC document
January 01, 2018 Filed Jan 4, 2018 02:38 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 9,167 Not disclosed Not disclosed
Disclosure

SEC source: 0001144204-18-000676 · tv482655_4.xml · nonDerivative · entry 1

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,167

F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.